An interventional study of Photoacoustic imaging and multispectral imaging in Foot Ulcer, sponsored by State University of New York at Buffalo. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by State University of New York at Buffalo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Foot Ulcer with a site in United States — 21 open to participants now, 22 under way, 1 of them phase 3. Foot Ulcer · United States.
Among the 90 studies in Foot Ulcer with a site in United States, this one is the 58th largest by planned enrollment of the 75 interventional ones that give a count, is one of 8 that started in 2025, is one of 39 with no phase, reaches primary completion later than 13 of the 21 other live ones, and was the 87th registered.
196 studies on the registry are indexed under Foot Ulcer; 43 are open to participants now.
Browse Foot Ulcer studies →21 of the 90 studies in Foot Ulcer with a site in United States are open now. Recruiting first, the newest first:
BioLab Holdings · Sites in United States
Ages 18+
Applied Biologics, LLC · Sites in United States
Ages 18+
Applied Biologics, LLC · Sites in United States
Ages 18+
BioLab Holdings · Sites in United States
Ages 18+
Sequence LifeScience, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Foot Ulcer studies recruiting now, 27 (84%) set no upper age limit and 2 (6%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 9 · Phase 4 7
First in 1998; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 60 across 160 interventional studies indexed under Foot Ulcer.
Median enrollment 60 across the 75 interventional studies, 80 across the 14 observational. Of the 59 that completed or were terminated, 16 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 90 have an industry lead sponsor. The 10 most frequent:
State University of New York at Buffalo is the lead sponsor of 294 studies on the registry; 63 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
State University of New York at Buffalo has 1 study filed under Foot Ulcer — fewer than ten, so there is no comparison to draw.
12 of the studies in Foot Ulcer with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06449638StimLabsModified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs | 2026-11 |
| NCT06674980C5 BiomedicalClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs | 2026-11-22 |
| NCT03942081Linnea PolgreenDiabetic Foot Ulcer Imaging- Study 2 | 2026-12 |
| NCT07116876LifeNet HealthMatrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers | 2026-12-15 |
| NCT07364630BioLab HoldingsEfficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 90 studies in Foot Ulcer with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot device trial aims to test the feasibility of using photoacoustic images to monitor tissue perfusion and to guide post-surgical wound treatment. Through this pilot study, the investigators will test the feasibility, identify any practical issues, and acquire essential information (e.g., drop-off rate, variation in wound healing rate) to guide future large-scale studies.
This pilot device trial aims to test the feasibility of using photoacoustic images to monitor tissue perfusion and to guide post-surgical wound treatment. Through this pilot study, the investigators will test the feasibility, identify any practical issues, and acquire essential information (e.g., drop-off rate, variation in wound healing rate) to guide future large scale studies.
For recruited patients, wound care will be guided by both photoacoustic imaging and Kent imaging, a multi-spectral imaging technique for tissue oxygenation mapping. None of the techniques is currently used in the clinic as standard care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will undergo imaging using the investigational photoacoustic device.
Device: Photoacoustic imaging and multispectral imaging
Use photoacoustic and Kent imaging devices that can image vasculature and assess tissue perfusion on the foot.
Treatment fidelity rate
The ratio of cases received additional clinical assessment due to photoacoustic imaging results.
Time frame: 12 months
Percentile healing score
The healing score will be defined as the ratio of the healed wound area versus the pre-treatment wound area (1-(post-treatment wound area)/(pre-treatment wound area)). A percentile healing value of 100% indicates that the wound is fully healed, while a value of 0% indicates that the wound area does not change.
Time frame: 12 months
Recruitment rate
The ratio of recruited patients to the total number of eligible patients
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.
Of 36 non-industry interventional studies with no phase under Foot Ulcer, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 18 months is below that.
Counting every sponsor, half of 56 studies reached it within 25 months; a quarter within 9 and three quarters within 40.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2026 → Apr 2027 and completion Dec 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
State University of New York at Buffalo →